CEO Corner

Building Biotech Champions: Cultivating Breakthroughs In A Dynamic Field

Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an agile team with a championship mindset.

Balanced Disruption: Leading Change In A Family-Owned Pharma Company

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO Stefan König.

Winning With The Right Marbles: The Future of Generics

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO Stephen Beckman.

Planning For Perseverance

AC Immune SA cofounder and CEO Andrea Pfeifer offers lessons in strategy and resilience for building and maintaining a drug development company amid internal and external ups and downs.

Leading Through Biotech's Perfect Storm: Lessons From The Front Lines

Memo Therapeutics CEO Erik van den Berg reflects on the strategies and skills needed to build company resilience and navigate successfully through challenging external circumstances.

How To Lead a Company That's Disrupting An Industry

Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.

From Bike Mechanic To Surgeon To CEO

InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, surgeon, and biopharmaceutical leader.

Navigating Growth In Biotech: A First-Person Insight

Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value.

Delivering The Next Evolution In Immuno-Oncology

To continue the momentum created by new discoveries and treatments for cancer patients, drug developers need a strong and focused corporate culture, employees willing to challenge established norms, and a system for prioritizing development candidates guided by science and patient needs.

Facing The Drug Launch Challenge As A New CEO

Economic instability, geopolitical struggles, market access, pricing, and regulatory differences — among many other issues — can present themselves at any time before, during, or after the launch. What is important is how a CEO manages the steps toward launch success.